Psoriasis occurs with increased incidence in patients with bullous pemphigoid (BP). In this article, we describe the seventh reported English literature case in which the bullous lesions were limited to psoriatic plaques, and we discuss the pathophysiologic mechanisms that might explain this phenomenon. Treatment with acitretin quickly cleared both psoriatic and bullous lesions, suggesting a direct link between the psoriatic inflammatory process and the evolution of bullous lesions.

Bullous pemphigoid (BP) limited to psoriatic plaques was first reported by Person and Rogers\(^1\) in 1976. Subsequent cases were reported by Abel and Bennett\(^2\) in 1979, Grunwald et al\(^3\) in
1985 (2 cases), Smith et al in 1991, and Kirtschig et al in 1996. In all 6 cases, blisters cleared when psoriatic lesions resolved, suggesting a pathogenic link. In this article, we report a seventh English literature case of BP limited to psoriatic plaques and consider pathogenic mechanisms that could account for this association.

**Case Report**
A 47-year-old Hispanic man with a 2-year history of chronic plaque psoriasis presented with a 2-week flare thought to be secondary to a recent upper respiratory tract infection. Treatment consisted of calcipotriene ointment only. Prior treatment included topical steroids and UVB light, which the patient discontinued one year earlier. The patient reported drinking approximately 12 oz of beer each day. Numerous well-demarcated erythematous plaques were noted over the trunk, buttocks, scalp, and extremities; some of these plaques had a thick scale, and many were confluent. Vesicles and bullae were limited to the junction of psoriatic plaques and normal skin on the right chest and bilaterally on the peripheral axillae. A few erosions also were noted within the plaques themselves.

Results of complete blood cell count, routine chemistry panel, urinalysis, thyroid stimulating hormone test, and lipid panel were normal. Results of liver function tests were mildly elevated: alkaline phosphatase, 172 U/L (reference range, 35–106 U/L); alanine aminotransferase, 88 U/L (reference range, 3–55 U/L); and \( \gamma \)-glutamyl transpeptidase, 269 U/L (reference range, 5–109 U/L). Results of total protein, albumin, aspartate aminotransferase, total bilirubin, conjugated bilirubin, and indirect reacting bilirubin tests were normal. Results of hepatitis B and C panels were negative. A hepatitis A IgG antibody test was positive, consistent with past history of hepatitis A. Throat culture was negative, but serum antistreptococcal O titer was 333 Todd units (reference range, <100 Todd units), consistent with recent streptococcal infection. Results of bacterial and viral cultures of the vesicles were negative.

A punch biopsy specimen from a vesicular lesion showed a subepidermal vesicle with eosinophils (Figure 1). Results of direct immunofluorescence of perilesional skin showed trace linear IgG and 3+ linear continuous C3 at the dermal-epidermal junction (Figure 2). IgM, IgA, and fibrin were negative. Indirect immunofluorescence with the patient's serum on salt-split skin was negative.

The patient was treated for 2 weeks with levofloxacin, phenylpropanolamine, and guaifenesin for symptoms of a sinus infection. Topical clobetasol and calcipotriene had little effect on either the psoriatic plaques or the vesicles and bullae. Acitretin was started at 25 mg/d. Within 2 weeks, all vesicular and bullous lesions resolved completely; after one month, the psoriasis was significantly improved. Then the acitretin dosage was increased to 50 mg/d. The psoriatic plaques cleared, and the vesicular lesions did not recur. After one year of treatment, the patient was still almost completely clear of psoriatic plaques, and vesicular lesions had not recurred. Liver function tests normalized after one month of stopping alcohol intake and beginning acitretin therapy, and lipid levels remained within reference range.

**Comment**
Our patient’s case of BP seemed to have been restricted to psoriatic plaques. Epidermolysis bullosa
acquisita (EBA) remained a diagnostic consideration because of a negative indirect immunofluorescent study. However, the rapid response to therapy supported a diagnosis of BP rather than EBA.

Psoriasis and BP cooccur with an incidence greater than would be expected by chance alone. The limitation of bullous lesions to psoriatic plaques further supports the association of these diseases. Other immunobullous diseases reported less commonly with psoriasis include pemphigus vulgaris, pemphigus foliaceus, EBA, pemphigus erythematosus, and systemic lupus erythematosus.

Numerous reports of other inflammatory skin diseases associated with immunobullous disorders support the theory that immunobullous disorders may be induced by tissue injury in genetically predisposed individuals—perhaps by unmasking or exposing antigenic sites in the basement membrane zone (BMZ). "Epitope spreading" is thought to occur through similar mechanisms with the development of new antibodies to recently unveiled antigenic sites. Once "sensitized," the antibodies become pathogenic. Lichen planus pemphigoides likely represents a similar pathogenic process.

No BP lesions occurred independent of psoriatic lesions in our patient, indicating either that the antibody alone was not pathogenic or that the titer was too low to produce lesions on normal skin. Also, bullous lesions occurred in typical BP distribution (peripheral axillae). As BP antigen expression is highest in the flexures, it may affect lesion distribution. Perhaps the presence of activated lymphocytes in these areas of high antigen concentration provided adequate stimulation for the development of autoimmunity. Another possibility is that psoriatic skin expresses higher BP antigen levels than normal skin does, which would explain cases of bullous disease limited to psoriatic plaques.

Alterations in the BMZ of psoriatic skin cause basal keratinocyte herniation through electronlucent areas in the lamina densa and through areas where basal keratinocytes are detached from the BMZ or are resting directly on the papillary dermis without the interposition of the lamina densa. These alterations may provide easier antigen access to low-titer antibodies or may initiate autoimmunity. In many reported cases of BP associated with psoriasis, UV light or aggressive topical therapy was thought to be the inducing agent. UV light can induce BP, perhaps by inducing antigenic changes in basal keratinocytes. In our patient, there was no correlation with UV light exposure, and topical therapy was limited to calcipotriene. According to a 1990 study, human neutrophil elastase may be involved in the destruction of the dermal-epidermal junction in psoriatic plaques. Incubation of normal skin with human neutrophil elastase destroys hemidesmosomes and separates epidermis from dermis above the level of the BP antigen. Other enzymes that may have a role are neutral proteases, elastase, cathepsin, serine proteinases, and plasminogen activator.
produced by keratinocytes is thought to be the predominant complement factor in the BMZ in autoimmune and inflammatory skin disorders (likely contributing to the inflammatory milieu in the BMZ). 28

In 1990, Baird et al 29 reported increased levels of plasminogen activator in skin with psoriasis and BP but not in normal skin. We postulate that BP was limited to psoriatic plaques because antigens at these sites were unmasked through enzymatic degradation of the BMZ, allowing easier access to circulating low-titer antibodies. Our patient’s bullous lesions resolved quickly after his psoriasis had been controlled with acitretin—thus supporting a direct pathogenic link.

Treatment of patients with cooccurring psoriasis and BP presents special problems. Systemic steroids, in general, should be avoided when treating psoriasis, and UV light should be avoided when treating BP. Methotrexate, 5,21,24,30 dapsone, 31 cyclosporine, 32,34 cyclophosphamide, 25 mycophenolate mofetil, 35 topical steroids, 2,3,10 etretinate, 9 and azathioprine 36,37 have all been used to successfully treat the coexisting diseases. Of the 6 reported cases of BP limited to psoriatic plaques, one case resolved without treatment, 1 3 resolved with topical steroids, 2,3 one resolved with oral prednisone (low maintenance dose), 4 and one resolved with methotrexate. 5 In all 6 cases, psoriasis tended to be more problematic than BP, obviating the need for aggressive or long-term systemic therapy directed at the immunobullous disease. Our patient’s BP lesions completely resolved within 4 weeks of starting acitretin.

In summary, we have reported the seventh English literature case of BP associated with psoriasis in which the immunobullous disease was restricted to psoriatic plaques. Unmasking of antigenic determinants in the BMZ by the psoriatic inflammatory process is postulated. This unmasking leads to de novo antibody synthesis in genetically predisposed individuals or to clinical disease in individuals with subclinical antibody titers.

REFERENCES